Biggest News Aggregation in the World
📰 Query Advisor News

Query Advisor News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Query Advisor. Real-time updates on events, politics, business and more.

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Bimekizumab treatment led to superior improvements in joint and skin efficacy outcomes at week 16 compared with placebo in patients with psoriatic arthritis and inadequate response or intolerance to TNFα inhibitors. The safety profile of bimekizumab was consistent with previous phase 3 studies in patients with plaque psoriasis, and studies of IL-17A inhibitors.
Eteläuomen Läi United States United Kingdom Czech Republic Health Assessment Questionnaire Health Survey

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science